Atlas Trials

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

Clinical trial NCT04106843 · WITHDRAWN

Trial details

NCT number
NCT04106843
Sponsor
M.D. Anderson Cancer Center
Status
WITHDRAWN
Phase
Phase 2
Study type
INTERVENTIONAL
Locally Advanced Adrenal Gland PheochromocytomaLocally Advanced ParagangliomaMetastatic Adrenal Gland PheochromocytomaMetastatic ParagangliomaMetastatic Parathyroid Gland CarcinomaPituitary Gland CarcinomaSomatostatin Receptor PositiveStage III Thyroid Gland Medullary Carcinoma AJCC v8Stage IV Thyroid Gland Medullary Carcinoma AJCC v8Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8
Start date
2019-06-13
Primary completion
2020-09-03
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.